959
Views
17
CrossRef citations to date
0
Altmetric
Original Article

Challenges and opportunities in insomnia disorder

ORCID Icon, , , ORCID Icon, &
Pages 1058-1065 | Received 03 Mar 2020, Accepted 19 May 2020, Published online: 01 Jun 2020
 

Abstract

Background

Insomnia disorder is a prevalent, often unrecognized condition that affects millions. This clinical disorder is characterized by difficulty initiating or maintaining sleep over a sustained period. In fact, insomnia disorder affects much more than sleep; it increases the risk of developing serious medical and psychiatric comorbidities and can exacerbate existing conditions. The association between insomnia disorder and serious medical and psychiatric comorbidities are complex and directionality is not yet fully understood. There remain gaps in the treatment landscape for insomnia disorder.

Methods

We performed a narrative review of the published literature to identify challenges, unmet needs, and burden associated with insomnia disorder.

Results

In this article, we describe the substantial burden that insomnia disorder poses on patients, the healthcare system, and society in the US. This article explores the factors attributable to this burden including limited provider knowledge, inadequate treatment options, and unknown long-term impacts of off-label treatments.

Conclusions

Several recommendations are proposed to address these challenges and improve patient outcomes through efforts to: (1) establish the societal value of treatment; (2) improve the clinical understanding of insomnia disorder; and (3) prioritize development of and access to effective treatments that do not pose addiction potential or tolerability issues.

Disclosure statement

M. Roach, R. Tuly, and J.W. Chou are employees of PRECISIONheor, a consulting firm that received research funding from Eisai Inc. J.W. Chou also owns stock in Precision Medicine Group, the parent company of PRECISIONheor. T. Juday is an employee of Eisai Inc. A. B. Jena is a consultant for PRECISIONheor. P.P. Doghramji is a consultant for Eisai Inc.

Additional information

Funding

This study was funded by Eisai Inc.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.